Pazopanib is an oral targeted cancer medicine. It is a tyrosine kinase inhibitor (TKI) that acts on several proteins tumours rely on to grow, including VEGFR, PDGFR and KIT.
Approved uses
- Advanced renal cell carcinoma (RCC), the most common type of kidney cancer
- Advanced soft tissue sarcoma in patients who have previously received chemotherapy
Pazopanib is not approved for every type of soft tissue sarcoma. Your oncologist will confirm whether it is suitable for your diagnosis.
How does it work?
Tumours need a blood supply to grow. Pazopanib blocks signals that stimulate the growth of new blood vessels (angiogenesis), which can slow the growth and spread of the cancer.
How is it usually taken?
Pazopanib is usually taken once a day on an empty stomach, at least one hour before or two hours after a meal. Tablets should be swallowed whole and not crushed. It is available as 200 mg and 400 mg tablets; your oncologist will tell you which strength and how many tablets make up your daily dose, and may adjust it during treatment.
Monitoring during treatment
Pazopanib can affect the liver. Your doctor will check liver blood tests before you start and regularly during treatment, especially in the first months. Blood pressure, thyroid function and heart rhythm may also be monitored.
Common side effects
- Diarrhoea
- High blood pressure
- Change in hair colour (lightening)
- Nausea, loss of appetite and tiredness
- Changes in taste
Contact your doctor promptly if you notice
- Yellowing of the skin or eyes, dark urine or pain in the upper right abdomen
- Unusual bleeding or bruising
- Chest pain, shortness of breath or a racing heartbeat
- Severe or persistent diarrhoea
Practical tips
- Avoid grapefruit and grapefruit juice, which can raise Pazopanib levels in the blood
- Tell your oncologist about all other medicines, including acid-reducing medicines, as some interact with Pazopanib
- Pazopanib may slow wound healing; tell your doctor if you are planning surgery or dental work
